Indolo[3,2- c ]isoquinoline Hydroxamic Acid Derivatives as Novel Orally Topoisomerase-Histone Deacetylase Dual Inhibitors for NSCLC Therapy
Journal of Medicinal Chemistry · 23.01.2025 · 68 (2) · 1300-1315
DOI: 10.1021/acs.jmedchem.4c01859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 23.10.2024. Verfasst von Bichuan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Department of Organic Chemistry, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Histone Deacetylase Inhibitors, Lung Neoplasms, Hydroxamic Acids. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Based on the synergistic effects of topoisomerase (Top) inhibitors and histone deacetylase (HDAC) inhibitors in cancer therapy, a series of novel Top/HDAC dual inhibitors were designed and synthesized herein. The optimal compound 31 was identified to simultaneously inhibit both Tops and HDACs with potent antiproliferative activity against nonsmall cell lung cancer (NSCLC). Mechanistic studies indicated that compound 31 with increasing reactive oxygen species levels damages DNA, inhibiting cancer cell colony formation and migration and inducing both cancer cell apoptosis and cycle arrest. Noteworthily, compound 31 was orally active in the NSCLC xenograft model, and its antitumor efficacy (TGI = 77.5%, 100 mg/kg) was superior to that of HDAC inhibitor SAHA and SAHA in combination with the Top inhibitor irinotecan. Consequently, this work highlights the therapeutic potential of compound 31 as the Top/HDAC dual inhibitor in NSCLC therapy and provides valuable lead compounds for the further development of antitumor agents in solid tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Department of Organic Chemistry, China Pharmaceutical University, Nanjing 210009, China.
- The Department of Urology Surgery, Changhai Hospital, Second Military Medical University (Naval Medical University), Shanghai 200433, China.
- The Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Second Military Medical University (Naval Medical University), Shanghai 200433, China.
ORCID-Profile: Bichuan Wang, Chunquan Sheng, Qingfa Zhou
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, B., Shi, T., Jia, S., Wang, E., Ruan, X., Sheng, C., Wu, S., & Zhou, Q. (2025). Indolo[3,2- c ]isoquinoline Hydroxamic Acid Derivatives as Novel Orally Topoisomerase-Histone Deacetylase Dual Inhibitors for NSCLC Therapy. Journal of Medicinal Chemistry, 68(2), 1300-1315. https://doi.org/10.1021/acs.jmedchem.4c01859
Vancouver
Wang B, Shi T, Jia S, Wang E, Ruan X, Sheng C, et al. Indolo[3,2- c ]isoquinoline Hydroxamic Acid Derivatives as Novel Orally Topoisomerase-Histone Deacetylase Dual Inhibitors for NSCLC Therapy. Journal of Medicinal Chemistry. 2025;68(2):1300-1315. doi:10.1021/acs.jmedchem.4c01859
BibTeX
@article{Wang2025,
author = {Wang, Bichuan and Shi, Ting and Jia, Shuolei and Wang, Enyuan and Ruan, Xiuqin and Sheng, Chunquan and Wu, Shanchao and Zhou, Qingfa},
title = {Indolo[3,2- c ]isoquinoline Hydroxamic Acid Derivatives as Novel Orally Topoisomerase-Histone Deacetylase Dual Inhibitors for NSCLC Therapy},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {2},
pages = {1300--1315},
doi = {10.1021/acs.jmedchem.4c01859}
}
EUVIMED